Orthocell Ltd finished the March 2025 quarter with major progress towards commercialising its regenerative medicine portfolio, headlined by the post-quarter US Food and Drug Administration (FDA) clearance for its flagship Remplir™ nerve repair device.
Clearance for Remplir™ under the FDA’s 510(k) pathway was granted on April 3, 2025, positioning the company to begin distribution into the US$1.6 billion nerve repair market. With logistics and sales pathways already in place and a US-based commercial team active since November 2024, Orthocell expects to generate its first US revenue from Remplir™ within the current financial year.
To support this anticipated growth, Orthocell has scaled its manufacturing capabilities to produce up to 100,000 units annually, with additional low-capital expansion capacity available. The company also built significant inventory during the quarter in preparation for US market entry and successfully hosted a pre-launch event at the 2025 IFSSH and IFSHT Triennial Congress in the United States.
“Our primary focus this quarter has been to ensure we were ready to deliver Remplir sales into the US as soon as practical following receipt of FDA clearance. We’ve been working on the basis we would be successful with the FDA and it was extremely gratifying to see approval come through immediately after the end of the quarter,” Orthocell CEO and MD, Paul Anderson, said.
“We expect this to be a significant revenue inflection point for us, so a major component of our activities over this quarter has been on-the-ground in the US with a focus on pre-launch sales activities and ensuring logistics are in place. I’m pleased to say we’re ready to go.”
“We have also maintained the strong sales levels from the previous quarter and continue to receive excellent feedback from surgeons, which in turns gives us confidence as we enter the US market with Remplir.”
Revenue trajectory
Financially, Orthocell delivered its fourth consecutive quarter of strong revenue, reporting A$2.22 million for the period—consistent with the December quarter and up 38% on the prior corresponding period. The company’s revenue trajectory continues to reflect strong uptake of its Striate+™ and Remplir™ products, particularly in Australia.
Net cash inflows from operating activities totalled $605,000 for the quarter, primarily driven by the government’s Research and Development (R&D) Tax Incentive program. Expenditure during the period was directed towards both commercial operations and ongoing R&D initiatives.
Orthocell closed the quarter with a robust cash balance of A$31.7 million and no debt, positioning it to sustain global commercialisation efforts without requiring material capital expenditure for the US launch. The company employs a cost-efficient sales model using distributors globally and a targeted internal sales presence in the US.
Market expansion
Further regulatory submissions during the quarter aim to expand the reach of Remplir™, with applications lodged in Canada and Thailand, targeting entry into the US$75 million and US$84 million markets respectively by late 2025.
Meanwhile, the rollout of Striate+™ continues under global distribution partner BioHorizons, with first sales recorded in Germany, Austria and Switzerland, and regulatory approval granted in Singapore.
Capping off the quarter, Orthocell was added to the S&P/ASX All Ordinaries Index following the March 2025 index rebalance, reinforcing its growing presence in the Australian biotechnology landscape.